KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Liabilities (2016 - 2025)

CRISPR Therapeutics AG's Total Liabilities history spans 11 years, with the latest figure at $343.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 10.8% year-over-year to $343.4 million; the TTM value through Dec 2025 reached $343.4 million, up 10.8%, while the annual FY2025 figure was $343.4 million, 10.8% up from the prior year.
  • Total Liabilities for Q4 2025 was $343.4 million at CRISPR Therapeutics AG, up from $329.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $399.4 million in Q3 2022 and bottomed at $152.4 million in Q1 2021.
  • The 5-year median for Total Liabilities is $349.6 million (2021), against an average of $337.8 million.
  • The largest annual shift saw Total Liabilities soared 137.03% in 2022 before it dropped 11.86% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $352.4 million in 2021, then grew by 4.3% to $367.6 million in 2022, then fell by 5.66% to $346.8 million in 2023, then dropped by 10.62% to $310.0 million in 2024, then grew by 10.8% to $343.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Total Liabilities are $343.4 million (Q4 2025), $329.3 million (Q3 2025), and $318.6 million (Q2 2025).